Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ.
Faderl S, et al. Among authors: pro b.
Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9.
Blood. 2003.
PMID: 12522009
Free article.
Clinical Trial.